Research programme: T-cell adoptive immunotherapy - Cellectis

Drug Profile

Research programme: T-cell adoptive immunotherapy - Cellectis

Alternative Names: UCART 22; UCART 38; UCART CS1

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cellectis
  • Developer Cellectis; Pfizer; Servier; University College London
  • Class CAR-T cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 27 Jul 2017 Cellectis and MolMed agree to develop and produce allogeneic CAR-T products for Cancer
  • 24 Jul 2017 Cellectis receives grant by the European Patent Office for CRISPR technology
  • 29 Jun 2017 Servier in-licenses viral vectorization technology from Transgene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top